Article Text

Download PDFPDF
Idiopathic pulmonary fibrosis: is all-cause mortality a practical and realistic end-point for clinical trials?
  1. Tamera Jo Corte1,2,
  2. Nicole S Goh3,
  3. Ian N Glaspole4,
  4. Christopher J Zappala5,
  5. Peter M Hopkins6,
  6. Margaret L Wilsher7
  1. 1Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
  2. 2University of Sydney, Sydney, New South Wales, Australia
  3. 3Department of Respiratory and Sleep Medicine, Austin Health, Melbourne, Victoria, Australia
  4. 4Department of Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia
  5. 5Department of Respiratory Medicine, Royal Brisbane Hospital, Brisbane, Queensland, Australia
  6. 6Department of Pulmonary Transplantation and Vascular Medicine, Prince Charles Hospital, Brisbane, Queensland, Australia
  7. 7Department of Respiratory Medicine, Auckland Hospital, Auckland, New Zealand
  1. Correspondence to Dr Tamera Jo Corte, Department of Respiratory Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney, NSW 2050, Australia; tameracorte{at}mac.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Dear Editor,

We read with interest the article by Wells et al1 in which the problematic selection of primary end-points for treatment studies in idiopathic pulmonary fibrosis (IPF) patients is addressed. In this document endorsed by respiratory physicians across Europe, the authors explore the implications of using all-cause mortality as a primary end-point in response to a recent statement by a working group on this topic.2 In a rather controversial statement by this working group, Raghu et al suggested that all-cause mortality and all-cause non-elective hospitalisation are the strongest and cleanest clinically meaningful end-points for use in Phase 3 clinical …

View Full Text

Footnotes

  • Contributors All authors contributed to the authorship of this correspondence.

  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.